—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Corcept Therapeutics Incorporated (CORT) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CORT, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelooknet

Where CORT appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.78 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How CORT has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.78 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Corcept Therapeutics Incorporated moved 0.78% on average · correlation 0.09 · higher than 76% of US names
  • Beta, last 3 months 0.24 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.10% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +4.93% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against CORT on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Corcept Therapeutics Incorporated

CORT in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Corcept develops drugs that block cortisol receptors, treating disorders where the body produces too much of the hormone. Its approved medicine, Korlym, treats hyperglycaemia linked to Cushing's syndrome, and it is testing further cortisol modulators, including relacorilant and miricorilant, for other endocrine and neurologic conditions. It was incorporated in 1998 and is based in Redwood City, California.
Where it sits in the stack
Corcept carries no seat in our index and sits outside the AI-linked sleeves the diary tracks; it belongs to the Healthcare sector of our wider universe, grouped by country with other US-listed biopharmaceutical names.
Who it is priced against
The diary's peer group is drawn from scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene, plus device and services names such as Globus Medical and IDEXX Laboratories.
Why Closelooknet tracks it
Corcept holds no index seat but carries a Closelooknet score, with momentum the strongest module and valuation the weakest; the diary noted it once in a Midday 10 piece listing health-care names making fresh 52-week highs.
What the diary watches
Whether trial readouts on relacorilant or miricorilant shift the valuation module, which currently lags the rest of the scorecard.

Corcept Therapeutics Incorporated (CORT) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return no distribution in twelve months · buybacks 246 m USD in FY2025

Dividends and capital return

What CORT pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 246 m USD 1.9% of today's market value
  • Share count +5.7% in FY2025 85 m USD of stock-based compensation in the year
  • Capital returned 246 m USD · 173% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Corcept Therapeutics Incorporated (CORT)?

Corcept Therapeutics Incorporated trades as CORT on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is CORT in a Closelooknet index?

Not currently — Corcept Therapeutics Incorporated is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does CORT trade against its moving averages?

Uptrend stack intact: Trades +4.8% vs the 50-day and +70% vs the 200-day average, 5.4% below the 52-week high and +317.2% off the 52-week low; a golden cross printed 74 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Corcept Therapeutics Incorporated compare with its peers?

Against its peer group (Biotechnology · US), Corcept Therapeutics Incorporated (CORT) sits 5.4% below its 52-week high, 4.8% above its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to CORT in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Corcept Therapeutics Incorporated trade when bond yields rise?

Over the past year Corcept Therapeutics Incorporated had a beta of 0.78 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 76% of US names. On the 10 sessions in which long bonds fell most it moved −0.10% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Corcept Therapeutics Incorporated?

Corcept Therapeutics Incorporated appears in 1 Closelooknet piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelooknet said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Corcept Therapeutics Incorporated do?

Corcept develops drugs that block cortisol receptors, treating disorders where the body produces too much of the hormone. Its approved medicine, Korlym, treats hyperglycaemia linked to Cushing's syndrome, and it is testing further cortisol modulators, including relacorilant and miricorilant, for other endocrine and neurologic conditions. It was incorporated in 1998 and is based in Redwood City, California. The diary's peer group is drawn from scored Healthcare names in the US, including argenx, Regeneron, Vertex Pharmaceuticals and BeiGene, plus device and services names such as Globus Medical and IDEXX Laboratories.

Where does Corcept Therapeutics Incorporated sit in the AI build-out?

Corcept carries no seat in our index and sits outside the AI-linked sleeves the diary tracks; it belongs to the Healthcare sector of our wider universe, grouped by country with other US-listed biopharmaceutical names. Corcept holds no index seat but carries a Closelooknet score, with momentum the strongest module and valuation the weakest; the diary noted it once in a Midday 10 piece listing health-care names making fresh 52-week highs.

Does Corcept Therapeutics Incorporated pay a dividend?

No cash distribution shows in Corcept Therapeutics Incorporated’s price series over the last three years. In fiscal 2025 the company bought back 246 m USD of its own shares, 173% of that year’s free cash flow. The share count rose 5.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for CORT, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.